Cognition study: Modafinil
Official title Cognitive Strategies in Early Psychosis 1
ClinicalTrials.gov ID: NCT07231497
What this study is testing
What is Modafinil?
An investigational oral medication being studied as a potential treatment for cognition and decision‑making in psychosis spectrum disorders. Modafinil is designed to increase wakefulness by enhancing dopamine signaling in the brain.
Also referred to as Provigil.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if one dose of modafinil changes how people play decision‑making games and alters brain activity measured by EEG.
- Who it's for
- Adults who do not have psychosis or any related disorder.
- What's involved
- Participants will complete an interview, questionnaires, safety screens (blood draw, urine drug test, alcohol breath test), take one dose of modafinil, and play computer brain games while wearing an EEG cap before and after the dose.
- Time commitment
- A single day visit with a few hours of testing and monitoring.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 35. Healthy volunteers may be eligible.
You may be able to join if
- English proficiency, as determined by staff observation and participant self-report
- Estimated IQ at or above 70, as estimated by the cognitive assessments
- Is clinical stable, defined as outpatient status for at least one month prior to study participation
- Has clinically stable doses of medication for at least one month prior to study participation as determined by the PI
- Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have major increases or decreases in...
You likely can't join if
- Major neurological disorder
- History of head injury with or without prolonged consciousness
- Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk...
- Renal impairment, injury, or disease
- Hepatic impairment, injury, or disease
- Myocardial infarction or heart disease.
See the full eligibility criteria
- English proficiency, as determined by staff observation and participant self-report
- Estimated IQ at or above 70, as estimated by the cognitive assessments
- Is clinical stable, defined as outpatient status for at least one month prior to study participation
- Has clinically stable doses of medication for at least one month prior to study participation as determined by the PI
- Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have major increases or decreases in dosses, or additions or removal of medications in the past 30 days
- Participants are to have no changes to medications in the past 7 days before study medication administration (i.e., must have been on a stable dose for at least 7 days prior to receiving the study drug).
- Major neurological disorder
- History of head injury with or without prolonged consciousness
- Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk by participating
- Renal impairment, injury, or disease
- Hepatic impairment, injury, or disease
- Myocardial infarction or heart disease.
- The following cardiac symptoms requiring medical follow-up that, in the opinion of the investigator, would impede participation in the study or would put the participant at additional risk by participating
- Dsypnea
- Palpitations
- Orthopnea
- Pedal oedema
- Significant dizziness
- Syncope
- Claudication ---Low white blood cell count, or is diagnosed with leukopenia, neutropenia, or agranulocytosis
- Presence of unmanaged hypertension (\>140/90) or elevated resting heart rate (\>100 bpm)
- uACR \> 30 mg/g
- creatinine level \>0/95 mg/dL
- AST or ALT \>50 U/L
- Bilirubin \>1.2 mg/dL
- Total Protein \<6 g/dL
- Participant is pregnant, planning to become pregnant, or is breastfeeding
- Participant cannot pass the visual acuity test (e.g., a score lower than 20/25 on the Snellen)
- Takes medications or supplements that have major interactions with modafinil (e.g., ketamine, MAOIs, clomipramine, diazepam, propranolol, warfarin, amphetamine or dextroamphetamine, dexmethylphenidate or methylphenidate)
- Has an allergy to modafinil
- Is currently taking modafinil as a prescription
- Meets criteria for severe substance or alcohol use disorder within 3 months of enrollment
- Lifetime history of stimulant use disorder
- Clinician judgment
- Active suicidal ideation at screening or other appointments
- Previous intent to act on suicidal ideation with a specific plan and/or preparatory acts within 6 months of enrollment
- A suicide attempt within 6 months of enrollment
- Meets criteria for a depressive episode within the past month as determined by the diagnostic interview or for a severe or extremely severe depressive episode in the abbreviated battery within the past month
- Meets DSM-5 criteria for, or reports professional diagnosis of, a psychotic, bipolar, or autism spectrum disorder
- Has a family history (1st degree relative) of psychotic, bipolar, or autism spectrum disorder
- Is prescribed psychotropic medications or takes supplements with psychotropic effects (e.g., Nootropics)
- Unable or unwilling to provide informed consent
- Unable to demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in the research study
- Participant is illiterate
- Have engaged in significant cognitive training, in the opinion of the PI, in the last year
The study team makes the final eligibility decision.
Where it is enrolling
- Minneapolis, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 35 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Minneapolis, Minnesota, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.